0001562180-19-002194.txt : 20190403
0001562180-19-002194.hdr.sgml : 20190403
20190403172356
ACCESSION NUMBER: 0001562180-19-002194
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20190401
FILED AS OF DATE: 20190403
DATE AS OF CHANGE: 20190403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Azoy Alexander
CENTRAL INDEX KEY: 0001771961
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38155
FILM NUMBER: 19730122
MAIL ADDRESS:
STREET 1: 30699 RUSSELL RANCH ROAD, SUITE 140
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sienna Biopharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001656328
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273364627
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 30699 RUSSELL RANCH ROAD, SUITE 140
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
BUSINESS PHONE: (818) 629-2256
MAIL ADDRESS:
STREET 1: 30699 RUSSELL RANCH ROAD, SUITE 140
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
FORMER COMPANY:
FORMER CONFORMED NAME: Sienna Labs, Inc.
DATE OF NAME CHANGE: 20151020
3
1
primarydocument.xml
PRIMARY DOCUMENT
X0206
3
2019-04-01
0
0001656328
Sienna Biopharmaceuticals, Inc.
SNNA
0001771961
Azoy Alexander
30699 RUSSELL RANCH ROAD
SUITE 140
WESTLAKE VILLAGE
CA
91362
false
true
false
false
Chief Financial Officer
Common Stock
17500.00
D
Stock Options (Right to buy)
20.19
2027-12-01
Common Stock
25000.00
D
Stock Options (Right to buy)
15.08
2028-06-01
Common Stock
5600.00
D
Stock Options (Right to buy)
2.32
2029-01-01
Common Stock
8750.00
D
Stock Options (Right to buy)
2.32
2029-01-01
Common Stock
8750.00
D
Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer's common stock upon vesting. The award vests as to twenty-five percent (25%) of the total number of RSUs on July 1, 2019, twenty-five percent (25%) of the total number of RSUs on January 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.
Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from December 1, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1, 2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
/s/Timothy K. Andrews, attorney-in-fact for Alexander Azoy
2019-04-03
EX-24
2
azoy.txt
AZOYPOA
Sienna Biopharmaceuticals, Inc.
Power of Attorney
Know all by these presents, that the undersigned hereby constitutes
and appoints each of (i) the Chief Executive Officer of
Sienna Biopharmaceuticals, Inc., a Delaware corporation (the "Company"),
who is currently Frederick C. Beddingfield III, (ii) the Company's
Chief Financial Officer, who is currently Alexander Azoy, and (iii)
the Company's General Counsel, who is currently Timothy K. Andrews,
and their respective successors (including anyone serving in such
capacities on an interim or acting basis), signing singly, with full powers
of substitution, as the undersigned's true and lawful attorney-in-fact to:
1. prepare, execute in the undersigned's name and on the
undersigned's behalf, and submit to the U.S. Securities and
Exchange Commission (the "SEC") a Form ID, including amendments
thereto, and any other documents necessary or appropriate to
obtain codes and passwords enabling the undersigned to make
electronic filings with the SEC of reports required by Section
16(a) of the Securities Exchange Act of 1934 or any rule or
regulation of the SEC;
2. execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer and/or director of the
Company, Forms 3, 4, and 5 and any amendments thereto in
accordance with Section 16(a) of the Securities Exchange Act of
1934 and the rules thereunder;
3. do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and
execute any such Form 3, 4, or 5, complete and execute any
amendment or amendments thereto, and timely file such form with
the SEC and any stock exchange or similar authority; and
4. take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorney-in-fact,
may be of benefit to, in the best interest of, or legally
required by, the undersigned, it being understood that the
documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's
discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all
intents and purposes as the undersigned might or could do if
personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do
or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that
the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4, and 5
with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 21 day of March, 2019.
/s/ Alexander Azoy
By: Alexander Azoy